NZ504894A - Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique - Google Patents

Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique

Info

Publication number
NZ504894A
NZ504894A NZ504894A NZ50489498A NZ504894A NZ 504894 A NZ504894 A NZ 504894A NZ 504894 A NZ504894 A NZ 504894A NZ 50489498 A NZ50489498 A NZ 50489498A NZ 504894 A NZ504894 A NZ 504894A
Authority
NZ
New Zealand
Prior art keywords
transdermal
transmucosally
animals
adjuvant compositions
separately administered
Prior art date
Application number
NZ504894A
Inventor
William F Swain
David Sarphie
Georg J Widera
Robert J Drape
Dexiang Chen
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US6714697P priority Critical
Priority to US8268698P priority
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Priority to PCT/US1998/025563 priority patent/WO1999027961A1/en
Publication of NZ504894A publication Critical patent/NZ504894A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse Transcribing DNA Viruses
    • C12N2730/00011Reverse Transcribing DNA Viruses
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

A method for enhancing the immune response to a selected antigen is disclosed. The method entails delivering a particulate adjuvant composition transdermally, preferably using a needleless syringe system. Also described are methods for forming crystalline particles from pharmaceutical compositions and then delivering the same to a subject. The crystallized compositions are particularly suitable for transdermal vaccine delivery using a needleless syringe system.
NZ504894A 1997-12-02 1998-12-02 Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique NZ504894A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US6714697P true 1997-12-02 1997-12-02
US8268698P true 1998-04-22 1998-04-22
PCT/US1998/025563 WO1999027961A1 (en) 1997-12-02 1998-12-02 Transdermal delivery of particulate vaccine compositions

Publications (1)

Publication Number Publication Date
NZ504894A true NZ504894A (en) 2002-12-20

Family

ID=26747529

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ504894A NZ504894A (en) 1997-12-02 1998-12-02 Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique

Country Status (9)

Country Link
EP (1) EP1035867A1 (en)
JP (1) JP2001524533A (en)
CN (1) CN1285753A (en)
AU (1) AU756828B2 (en)
CA (1) CA2312900A1 (en)
HU (1) HU0101139A3 (en)
IL (1) IL136488D0 (en)
NZ (1) NZ504894A (en)
WO (1) WO1999027961A1 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
US7022320B1 (en) 1999-02-09 2006-04-04 Powderject Vaccines, Inc. Mycobacterium tuberculosis immunization
AT534401T (en) 2000-10-18 2011-12-15 Glaxosmithkline Biolog Sa Mage antigen coupled to a protein d fragment containing vaccines
AT306938T (en) * 1999-06-29 2005-11-15 Glaxosmithkline Biolog Sa Use of cpg as adjuvans for hiv pulp
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6626871B1 (en) 1999-10-11 2003-09-30 Felton International, Inc. Method and apparatus for removing cap from medical device
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
AT374622T (en) * 1999-11-03 2007-10-15 Powderject Vaccines Inc Genetic insults with adjuvans
EP1913957B1 (en) * 1999-11-03 2010-03-17 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
IL149458D0 (en) * 1999-11-10 2002-11-10 Powderject Vaccines Inc Induction of mucosal immunity by vaccination via the skin route
AU2001275371B9 (en) * 2000-06-08 2007-06-07 Powderject Vaccines, Inc. Powder compositions
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
US8466116B2 (en) * 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AT500267T (en) 2003-07-21 2011-03-15 Transgene Sa Multifunctional cytokine
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
BRPI0515520A (en) 2004-09-22 2008-07-29 Glaxosmithkline Biolog Sa immunogenic composition, vaccine, methods of preparing a vaccine and preventing or treating staph infection, and use of immunogenic composition
CN102727885A (en) 2005-11-04 2012-10-17 诺华疫苗和诊断有限公司 Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ568212A (en) * 2005-11-04 2012-03-30 Novartis Vaccines & Diagnostic Changing Th1/Th2 balance in split influenza vaccines with adjuvants
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
PT1962899E (en) 2005-12-22 2011-10-19 Glaxosmithkline Biolog Sa Pneumococcal polysaccharide conjugate vaccine
SI2086582T1 (en) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
MX2009003325A (en) 2006-10-12 2009-04-09 Glaxosmithkline Biolog Sa Vaccine comprising an oil in water emulsion adjuvant.
SG170090A1 (en) 2006-03-30 2011-04-29 Glaxosmithkline Biolog Sa Immunogenic composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PL2054431T3 (en) 2006-06-09 2012-07-31 Conformers of bacterial adhesins
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
EA200901578A1 (en) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. Vaccine containing conjugates of capsular polysaccharides streptococcus pneumoniae
CN101969992B (en) 2007-09-12 2014-10-01 诺华股份有限公司 Gas57 mutant antigen and antibody gas57
EP2537857B1 (en) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O
EP2612680B1 (en) 2008-04-16 2018-05-23 GlaxoSmithKline Biologicals SA Vaccine
US8962026B2 (en) 2008-09-26 2015-02-24 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
US9278126B2 (en) 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
RU2011140508A (en) 2009-03-06 2013-04-20 Новартис Аг Chlamydia antigens
US9526778B2 (en) 2009-06-15 2016-12-27 Institut Pasteur De Lille Influenza vaccine, composition, and methods of use
JP6110140B2 (en) 2009-06-16 2017-04-05 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Nanoemulsion vaccine
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP5633152B2 (en) * 2010-02-16 2014-12-03 東ソー株式会社 Adjuvant
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
US9744228B2 (en) 2010-04-07 2017-08-29 Norvartis Ag Method for generating a parvovirus B19 virus-like particle
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
CN103154242B (en) 2010-07-06 2015-09-30 诺华股份有限公司 The immunogenic compositions and methods derived norovirus
GB2482691B (en) * 2010-08-10 2013-08-14 Nemaura Pharma Ltd Structures for transdermal drug delivery
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
AR086405A1 (en) 2011-05-17 2013-12-11 Glaxosmithkline Biolog Sa Streptococcus pneumoniae vaccine
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
EP2755994A2 (en) 2011-09-14 2014-07-23 Novartis AG Escherichia coli vaccine combination
EP2912069B1 (en) 2012-10-23 2019-07-31 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
KR101819803B1 (en) 2012-10-24 2018-01-17 플레이틀렛 타게티드 테라퓨틱스, 엘엘씨 Platelet targeted treatment
CA2928700C (en) 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
EP3068426A2 (en) 2013-11-13 2016-09-21 University Of Oslo Outer membrane vesicles and uses thereof
DK3069138T3 (en) 2013-11-15 2019-04-08 Oslo Univ Hf Ctl peptid epitopes and antigen-specific t-cells, methods of recognition thereof, and applications thereof
CA2931570A1 (en) 2013-12-03 2015-06-11 Virometix Ag Proline-rich peptides protective against s. pneumoniae
AR102548A1 (en) 2014-11-07 2017-03-08 Takeda Vaccines Inc Disease vaccines hands, feet and mouth and methods of manufacture and use
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
WO2018215433A1 (en) 2017-05-22 2018-11-29 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
TW201925222A (en) 2017-06-23 2019-07-01 美商醫院疫苗公司 Immunogenic compositions
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo Vaccine molecules
WO2019048928A1 (en) 2017-09-07 2019-03-14 University Of Oslo Vaccine molecules
WO2019090233A2 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509188A (en) * 1893-11-21 Barton b
US4629782A (en) * 1984-12-21 1986-12-16 Syntex (U.S.A.) Inc. Crystalline form of N-acetylmuramyl-L-α-aminobutyryl-D-isoglutamine
CA1337047C (en) * 1988-08-18 1995-09-19 Peter Dodd Cooper Gamma inulin compositions
DE69005679T2 (en) * 1989-03-29 1994-06-23 Takeda Chemical Industries Ltd Composition comprising a compound of the vitamin B group and their preparation.
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
AU5547594A (en) * 1992-11-03 1994-05-24 Secretech, Inc. Microcrystalline cellulose as an immune adjuvant
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
JP4117027B2 (en) * 1996-04-19 2008-07-09 オーバーン ユニバーシティー Nucleic acid vaccination for parvovirus infection

Also Published As

Publication number Publication date
CN1285753A (en) 2001-02-28
JP2001524533A (en) 2001-12-04
AU1619999A (en) 1999-06-16
AU756828B2 (en) 2003-01-23
EP1035867A1 (en) 2000-09-20
WO1999027961A1 (en) 1999-06-10
HU0101139A2 (en) 2001-07-30
HU0101139A3 (en) 2003-11-28
IL136488D0 (en) 2001-06-14
CA2312900A1 (en) 1999-06-10

Similar Documents

Publication Publication Date Title
Hunter et al. Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha.
Vogel Improving vaccine performance with adjuvants
Herbst et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease
JP4126067B2 (en) Adjuvant composition
McCluskie et al. CpG DNA is an effective oral adjuvant to protein antigens in mice
EP0761231B1 (en) Vaccine composition containing adjuvants
US5562910A (en) Vaccine compositions and method for enhancing an immune response
JP4731475B2 (en) QuilA fraction with low toxicity and use thereof
Heineman et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant
DE60029115T2 (en) Any pharmaceutical composition containing anything
Dullforce et al. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies
Tsung et al. IL-12 induces T helper 1-directed antitumor response.
Weis et al. Biological activities of native and recombinant Borrelia burgdorferi outer surface protein A: dependence on lipid modification.
Ilan et al. Adoptive transfer of immunity to hepatitis B virus after T cell–depleted allogeneic bone marrow transplantation
Ober et al. Vaccine-induced, pseudorabies virus-specific, extrathymic CD4+ CD8+ memory T-helper cells in swine
DE69615362T3 (en) Vaccine with a polysaccharidant bearing protein conjugate and a carrier protein
Czerkinsky et al. Mucosal immunity and tolerance: relevance to vaccine development
US5571515A (en) Compositions and methods for use of IL-12 as an adjuvant
Morein et al. Immunity in neonates
US6375945B1 (en) Adjuvant compositions for vaccines
Salvin et al. Brief communication: tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity
TW420617B (en) An oral sustained release opioid pharmaceutical composition and the method for preparing thereof
Playfair et al. Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice.
CA2388221C (en) Composition and method of cancer antigen immunotherapy
Leclerc et al. T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed